(Total Views: 657)
Posted On: 09/01/2020 6:00:40 AM
Post# of 154090
PR out - https://www.cytodyn.com/newsroom/press-releas...c-advisory
Global Health Leaders Join CytoDyn's Scientific Advisory Board
Download as PDFSeptember 01, 2020 6:00am EDT
Leading experts in the fields of HIV, Oncology, Rheumatology, and NASH join together to facilitate the best approaches to utilize multiple opportunities for leronlimab
VANCOUVER, Washington, Sept. 01, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced the formation and initial members of its Scientific Advisory Board today including leading HIV, NASH, Oncology, and Rheumatological clinical experts and researchers.
CytoDyn's Scientific Advisory Board members include Dr. Gero Hütter, German hematologist, best known for the bone marrow transplant resulting in the cure of the first HIV patient ; Dr. Hope S. Rugo, Professor, Department of Medicine (Hematology/Oncology) and Director of the Breast Oncology Clinical Trials Education Program at University of California San Francisco ; Dr. Richard T. Maziarz, Professor, Medical Director of the Adult Blood and Marrow Stem Cell Transplant and Cellular Therapy Program Knight Cancer Institute at Oregon Health & Science University (OHSU) ; Dr. Jonah B. Sacha, Professor, VGTI-Vaccine and Gene Therapy Institute at OHSU ; Dr. Mazen Noureddin, a hepatologist and Director, Cedars-Sinai Liver Transplant Program in Los Angeles ; Dr. Norman B. Gaylis, nationally and internationally recognized specialist in rheumatology and autoimmune diseases ; Dr. Eric D. Mininberg, Oncology Specialist, Piedmont Cancer Institute, a member of the MD Anderson Cancer Network; and Dr. Lishomwa Ndhlovu, Assistant Professor, Immunology, Department of Medicine, Division of Infectious Disease at Weill Cornell Medicine in New York .
Scott A. Kelly, M.D., Chief Medical Officer of CytoDyn, said, "This team of advisors is passionately committed to bringing new treatment options to patients facing some of the world's most challenging health conditions including HIV, cancer, NASH, and rheumatological disorders. We are grateful to be working with such a distinguished group of medical and academic professionals."
Dr. Kelly continued, "The combined years of medical practice, investigative trial experience and publications are more than impressive; we believe the collective wisdom and experience of these leaders will be the pathway to rapidly bringing leronlimab to the global health community. We will continue to expand this team with a focus on specific oncology indications, neurology, pulmonary and critical care, virology, and autoimmune diseases."
Global Health Leaders Join CytoDyn's Scientific Advisory Board
Download as PDFSeptember 01, 2020 6:00am EDT
Leading experts in the fields of HIV, Oncology, Rheumatology, and NASH join together to facilitate the best approaches to utilize multiple opportunities for leronlimab
VANCOUVER, Washington, Sept. 01, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced the formation and initial members of its Scientific Advisory Board today including leading HIV, NASH, Oncology, and Rheumatological clinical experts and researchers. CytoDyn's Scientific Advisory Board members include Dr. Gero Hütter, German hematologist, best known for the bone marrow transplant resulting in the cure of the first HIV patient ; Dr. Hope S. Rugo, Professor, Department of Medicine (Hematology/Oncology) and Director of the Breast Oncology Clinical Trials Education Program at University of California San Francisco ; Dr. Richard T. Maziarz, Professor, Medical Director of the Adult Blood and Marrow Stem Cell Transplant and Cellular Therapy Program Knight Cancer Institute at Oregon Health & Science University (OHSU) ; Dr. Jonah B. Sacha, Professor, VGTI-Vaccine and Gene Therapy Institute at OHSU ; Dr. Mazen Noureddin, a hepatologist and Director, Cedars-Sinai Liver Transplant Program in Los Angeles ; Dr. Norman B. Gaylis, nationally and internationally recognized specialist in rheumatology and autoimmune diseases ; Dr. Eric D. Mininberg, Oncology Specialist, Piedmont Cancer Institute, a member of the MD Anderson Cancer Network; and Dr. Lishomwa Ndhlovu, Assistant Professor, Immunology, Department of Medicine, Division of Infectious Disease at Weill Cornell Medicine in New York .
Scott A. Kelly, M.D., Chief Medical Officer of CytoDyn, said, "This team of advisors is passionately committed to bringing new treatment options to patients facing some of the world's most challenging health conditions including HIV, cancer, NASH, and rheumatological disorders. We are grateful to be working with such a distinguished group of medical and academic professionals."
Dr. Kelly continued, "The combined years of medical practice, investigative trial experience and publications are more than impressive; we believe the collective wisdom and experience of these leaders will be the pathway to rapidly bringing leronlimab to the global health community. We will continue to expand this team with a focus on specific oncology indications, neurology, pulmonary and critical care, virology, and autoimmune diseases."
(3)
(0)
